BSX
Boston Scientific Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 7.31M | $317.13M | n/a | n/a |
| Q2 2026 | 182 | -1 | 1.07B | $45.95B | +3 | −3 |
| Q1 2026 | 185 | -2 | 1.08B | $67.75B | +2 | −5 |
| Q4 2025 | 186 | +1 | 1.13B | $107.60B | +2 | n/a |
| Q3 2025 | 28 | 0 | 719.46M | $70.18B | n/a | −1 |
| Q2 2025 | 26 | -1 | 668.30M | $71.71B | n/a | −1 |
| Q1 2025 | 24 | +1 | 275.71M | $27.75B | +1 | n/a |
| Q4 2024 | 23 | -1 | 268.54M | $23.93B | n/a | −1 |
| Q3 2024 | 23 | +2 | 200.54M | $16.75B | +2 | n/a |
| Q2 2024 | 21 | n/a | 195.84M | $15.04B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 6.73M | -19.3% | $293.96M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 388.10K | +55.4% | $15.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 165.89K | -5.8% | $7.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Ninety One UK Ltd | 17.66K | -99.5% | $770,772 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,653 holders, 1.31B shares, $78.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 2.04K sh @ 49.22 · $100,408
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology